Main Menu

Immunoglobulins play a key role in the immune system. CDC has developed and tested hybridoma cell lines (monoclonal antibody (mAb) clones) for human IgG and other immunoglobulins. The mAbs generated from those hybridomas could be used as a reagent (second Ab) of anti-human immunoglobins in a diagnostic assay for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19 (coronavirus disease 2019) and other assays that detect antigen specific antibodies from human sera.

Rotaviruses cause severe gastroenteritis in humans and animals globally. Currently, there are eight known serogroups (A-H) of rotaviruses. Group C rotavirus (GpC RV) causes sporadic cases and outbreaks of acute diarrhea in children and adults worldwide. GpC RV is also associated with diarrhea in swine. Currently, no simple and reliable diagnostic test exists for GpC RV, so disease prevalence remains unknown.

Periodontal disease occurs in 10-20% of adults, and constitutes a major cause of tooth loss. About 0.5% of U.S. adolescents between the ages of 14 to 17 years old (about 70,000) have localized early onset periodontitis and 0.1% (17,000) have the more destructive form known as generalized early onset periodontitis. Both types of early onset periodontitis often lead to tooth loss before the age of 20. Extrapolation of these figures up to age 35 leads to estimates of early onset periodontitis having a major impact on the dental health of 400,000 individuals in the U.S. population.

Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection.

The current invention provides nucleic acid sequences comprising the genomes of infectious hepatitis C viruses (HCV) of genotype 1a and 1b. It covers the use of these sequences, and polypeptides encoded by all or part of the sequences, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV.

There is an acute deficit in chemical synthesis with respect to benchtop tools that are specifically designed to address the capability and efficiency of certain key aspects of chemical synthesis, namely reaction preparation, product isolation, and solvent removal. Chemical research currently relies upon a variety of devices that function in a manner that is disconnected, as well as difficult to integrate and automate; collectively, these device challenges hinder the efficient isolation and purification of desired chemical synthesis products.

This invention is a novel statistical method for automatically detecting lesions in cross-sectional brain magnetic resonance imaging (MRI) studies. OASIS uses multimodal MRI from one image acquisition session and produces voxel-level probability maps of the brain that quantifies the likelihood that each voxel is part of a lesion. Binary lesion segmentations are created from these probability maps using a validated population-level threshold. In this application, fluid attenuated inversion recovery (FLAIR), proton density (PD), T2-weighted, and Tl-weighted volumes were used.

The present invention is directed to a synthesis of a dual-target inhibitor of cannabinoid-1 (CB1R) receptor and inducible nitric oxide synthase, and more specifically, to an improved process for synthesis of (S,1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide.

Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried covalently bound complement activation fragments, especially C3d. NIH inventors have generated several C3d-specific mouse and rabbit monoclonal antibodies to re-target cells that have escaped from mAb therapy.

This invention includes human induced pluripotent stem cell (iPSC) lines that harbor a single copy dCas9-BFP-KRAB at the CLYBL safe harbor locus (mediating CRISPR inhibition of human gene expression) and/or a single copy of dox-inducible NGN2 at the AAVS1 locus (enabling the differentiation of the iPSCs into neurons). The CRISPR-mediated inhibition of human gene expression is maintained into the differentiated neurons, permitting functional studies of targeted genes in neurons.